MedTrace Logo

Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

NCT06368726 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-05-19

No results posted yet for this study

Summary

Results of the application of 100 sessions of tDCS for 12 months in children between 6 and 11 years old with autism spectrum disorder with rare diseases, genetic problems or PANDAS

Conditions

  • Attention
  • Visual Perceptual Weakness
  • Social Behavior
  • Fluency Disorder
  • EEG With Periodic Abnormalities

Interventions

DEVICE

tDCS or Transcranial Direct Current Stimulation

We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days

DRUG

Risperidone

Risperidone Risperidone according to child's weighs

Sponsors & Collaborators

  • Spanish Foundation for Neurometrics Development

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2025-12-12
Completion
2026-06-02
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06368726 on ClinicalTrials.gov